Sensydia Secures Oversubscribed Funding to Deliver Groundbreaking Cardiac Performance System to the Office, Hospital, and Clinic - BioSpace - 西甲联赛赛程

Round of more than $6 million, led by Colle Capital Partners with support from Orlando Health Ventures, will fund completion of Sensydia's ongoing ACOUSTIC*‑*1 study for the Cardiac Performance System (CPS™) and preparation for commercial launch. LOS ANGELES, Oct. 13, 2026 /PRNewswire/ -- Sensydia, a clinical-stage medical technology company advancing non-invasive cardiac assessment, today announced an oversubscribed initial closing of more than $6 million in its latest financing, led by Colle Capital Partners with substantial support from Orlando Health Ventures. "With Colle Capital and Orlando Health Ventures behind us, we are focused on bringing CPS to the market rapidly to help patients suffering from heart failure.". Sensydia is developing the Cardiac Performance System (CPS™), a non-invasive platform designed to give clinicians rapid, safe, and accurate assessments of hemodynamic function in the office or clinic, to help them better diagnose and manage heart failure and pulmonary hypertension and improve patient outcomes.